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Background/aims To investigate the efﬁcacy and
safety of the MGDRx EyeBag (The Eyebag Company,
Halifax, UK) eyelid warming device.
Methods Twenty-ﬁve patients with conﬁrmed
meibomian gland dysfunction (MGD)-related evaporative
dry eye were enrolled into a randomised, single masked,
contralateral clinical trial. Test eyes received a heated
device; control eyes a non-heated device for 5 min twice
a day for 2 weeks. Efﬁcacy (ocular symptomology, non-
invasive break-up time, lipid layer thickness, osmolarity,
meibomian gland dropout and function) and safety
(visual acuity, corneal topography, conjunctival
hyperaemia and staining) measurements were taken at
baseline and follow-up. Subsequent patient device usage
and ocular comfort was ascertained at 6 months.
Results Differences between test and control eyes at
baseline were not statistically signiﬁcant for all
measurements (p>0.05). After 2 weeks, statistically
signiﬁcant improvements occurred in all efﬁcacy
measurements in test eyes (p<0.05). Visual acuity and
corneal topography were unaffected (p>0.05). All
patients maintained higher ocular comfort after
6 months (p<0.05), although the beneﬁt was greater in
those who continued usage 1–8 times a month
(p<0.001).
Conclusions The MGDRx EyeBag is a safe and
effective device for the treatment of MGD-related
evaporative dry eye. Subjective beneﬁt lasts at least
6 months, aided by occasional retreatment.
Trial registration number NCT01870180.
INTRODUCTION
Eyelid warming therapy is considered the mainstay
of treating meibomian gland dysfunction (MGD).1
A variety of devices have been developed and
shown to be efﬁcacious in the treatment of MGD,
but many are not commercially available.2–6 More
recent studies focus on in-ofﬁce treatment proce-
dures, and have found long-term improvements in
MGD,7–10 but these may be reserved for severe
cases or those unresponsive to conventional
procedures.
There are no agreed-upon or standardised eyelid
warming procedures in the scientiﬁc literature.
Patient compliance issues relate to insufﬁcient
heating, duration and frequency of use.1 Studies
which have attempted to optimise treatment using
warm moist compresses suggest that precise and
intense treatment is required to maintain sufﬁcient
eyelid warming,11 which would require high com-
pliance and ability.
However, the MGDRx EyeBag (eyebag), a com-
mercially available eyelid warming device, may
allow for improved compliance owing to its simple
design. A recent study found that it produced sig-
niﬁcant increases in tear ﬁlm lipid layer thickness
and break-up time in healthy subjects.12 Increases
in temperature sufﬁcient to melt meibum1 was also
observed on the upper and lower internal and
external eyelids, suggesting it may be effective in
treating MGD and evaporative dry eye caused by
an ineffective tear ﬁlm lipid layer.12 The aim of this
study was to therefore investigate the efﬁcacy and
safety of the eyebag in patients with MGD-related
evaporative dry eye.
MATERIALS AND METHODS
The study was a randomised, contralateral (one-test
eye, fellow eye control), examiner-masked clinical
trial, received ethical approval from the Aston
University Research Ethics Committee and was
registered as a clinical trial (NCT01870180:
ClinicalTrials.gov). The research was conducted in
accordance with the principles expressed in the
Declaration of Helsinki.
Subjects
Subjects were identiﬁed during routine eye examin-
ation in a local primary care optometry practice,
and were required to be ≥18 years old, with no sys-
temic disease or medications known to affect the
eyes, and no other active eye disease except symp-
tomatic MGD-related evaporative dry eye.
Diagnosis of at least mild severity was based upon
recommendation by the diagnostic subcommittee
of the International Workshop on Meibomian
Gland Dysfunction: Ocular Surface Disease Index
(OSDI) score of >12; presence of meibomian
gland oriﬁce plugging/obstruction on the lower or
upper eyelids of both eyes; abnormal meibomian
gland function in at least one eye (≤20 years old:
quality or expressibility score >1; >20 years old:
quality and expressibility score ≥1; see below).13
Non-invasive tear ﬁlm break-up time (NITBUT)
<10 s in at least one eye, and a negative
Schirmer-1 test (>5.5 mm after 5 min) in at least
one eye to differentiate between evaporative and
aqueous deﬁciency dry eye.13 Eligible subjects were
enrolled with written informed consent and
attended for a baseline visit (Day 0) where the fol-
lowing battery of tests were performed in sequence.
Effectiveness measures
Ocular symptomology: dry eye symptoms were
assessed for each eye using the OSDI.
Bilkhu PS, et al. Br J Ophthalmol 2014;0:1–5. doi:10.1136/bjophthalmol-2014-305220 1
Clinical science
 BJO Online First, published on July 4, 2014 as 10.1136/bjophthalmol-2014-305220
Copyright Article author (or their employer) 2014. Produced by BMJ Pub ishing Group Ltd under licence. 
 group.bmj.com on July 15, 2014 - Published by bjo.bmj.comDownloaded from 
Meibomian gland function: based upon meibum quality and
expressibility using a slit-lamp.13 Quality and expressibility of
meibum from the central 8 meibomian glands on the lower and
upper eyelid was graded on a 4-point scale (quality: 0=clear
ﬂuid, 1=cloudy ﬂuid, 2=cloudy particulate ﬂuid, 3=inspissated
like toothpaste; expressibility: 0=all glands expressible, 1=3–4
glands expressible, 2=1–2 glands expressible, 3=no glands
expressible) following ﬁrm digital pressure to the eyelid
margins. Scores from the upper and lower eyelids were added to
give a composite value for quality and expressibility.
Meibomian gland dropout: measured via infrared meibogra-
phy using the Keratograph 5M (Oculus Optikgeraete GmbH,
Wetzlar, Germany) for the central 15 meibomian glands in the
upper and lower everted eyelids of each eye. Meibomian gland
dropout was graded using a 4-point scale (1=no partial glands;
2≤25% partial glands; 3=25–75% partial glands; 4≥75% partial
glands). A partial gland was deﬁned as one that is incomplete
(presumed relative to the length of neighbouring intact meibo-
mian glands) and present in lumps or clusters.13 Scores from the
upper and lower eyelids were added to give a composite value.
Tear ﬁlm osmolarity: measured in each eye using the
OcuSense TearLab (TearLab Corporation, San Diego, USA). Two
measurements were taken in random order from each eye and
were averaged to give a mean value for each eye.14
Tear ﬁlm lipid layer thickness: measured non-invasively using
a slit-lamp-mounted TearScope (Keeler, Windsor, UK) for each
eye in random order. The thickness range of the tear ﬁlm lipid
layer was deduced from interference patterns observed using a
standardised grading scale, where Grade 1=13–50 nm; Grade
2=30–50 nm; Grade 3=50–70 nm; Grade 4=80–90 nm; Grade
5=90–180 nm; Grade 6≥200 nm.15
Tear ﬁlm stability: was determined by assessing the NITBUT
using a slit-lamp-mounted TearScope on each eye in random
order. NITBUT was deﬁned as the time between the last com-
plete blink and the appearance of a break or distortion in the
ﬁne grid pattern. This was repeated two more times, and the
values were averaged to give a mean value.15
Tear Film Meniscus Height (TMH): measured using the
Keratograph 5M. Images of the right and left eyes in primary
gaze were captured immediately postblink. Digital callipers were
used to measure the TMH located directly below the centre of
the pupil, and was deﬁned as the distance between the lower
eyelid margin and the upper limit of the reﬂective zone—repeat-
ability 95% CI±0.06 mm.
Safety measures
Visual acuity: best corrected monocular and binocular visual
acuity was measured using a digital logMAR chart at 6 m, ran-
domised between presentations (Test Chart 2000; Thomson
Software Solutions, London, UK). Visual acuity was determined
using letter by letter scoring with each letter corresponding to
−0.02 logMAR units.
Corneal topography: was measured on each eye using the
Keratograph 5M.
Conjunctival hyperaemia: digital images of the nasal and tem-
poral bulbar conjunctiva were captured and analysed to provide
an objective measurement via edge detection and colour
extraction.16
Ocular surface staining: damage to the conjunctiva and cornea
was assessed via instillation of lissamine green (GreenGlo, Sigma
Pharmaceuticals, Monticello, USA) and ﬂuorescein sodium
(Fluorets, Chauvin Pharmaceuticals, London, UK) on each eye.
Corneal, nasal and temporal bulbar conjunctival staining was
graded individually using the Oxford system on a 6-point scale
(0–5) to provide a composite score (0–15) for each eye.17
Intervention
Subjects were then randomised to receive a heated eyebag (40 s
in microwave on full power) on either the left or right eye (test),
chosen by random number generation. The contralateral eye
received a non-heated eyebag (control). Subjects were instructed
to use the eyebags at the same time twice a day (morning and
evening, separated by at least 12 h) for 2 weeks (Days 1–14) and
were required to provide feedback—subjects were texted twice a
day (morning and evening) to grade ocular comfort for each eye
on a 1–10 scale immediately before applying the eyebags
(1=poor, 10=excellent). This score was also obtained at base-
line. The examiner was masked to which eye received the heat
treatment. Subjects then attended for follow-up (Day 15) where
the baseline measurements were repeated, and were left with
the eyebags to maintain their treatment if they felt it beneﬁcial.
Subsequent patient usage and reported ocular comfort (1–10
scale) was ascertained at 6±1 months.
Statistics
Statistical analysis was performed using SPSS for Microsoft
Windows (Chicago, Illinois, USA). Differences between control
and test eyes for visual acuity, ocular symptomology, corneal
topography, conjunctival hyperaemia, and tear ﬁlm stability,
meniscus height, and osmolarity were evaluated by paired t
tests, where the normal distribution was conﬁrmed
(Kolmogorov–Smirnov test: p>0.05). Differences between
control and test eyes for non-normally distributed measures of
tear ﬁlm lipid layer thickness, meibomian gland function and
dropout, and staining were evaluated by the Wilcoxon
signed-rank test. Changes in ocular comfort scores over time
were evaluated using Friedman’s test, and posthoc analysis was
performed using Wilcoxon signed-rank tests. To detect a
primary treatment effect of 1 unit change in meibomian gland
dropout (β=0.2, α=0.05), 23 subjects were required as each
subject acted as their own control based upon published data
(SD in MGD patients=±1.7 per eight glands).18 To account for
possible drop-out, 25 patients (19 female, 6 male) were enrolled
and completed the clinical trial (mean age: 28.7±7.8 years;
range 19–42 years).
RESULTS
At baseline, there was no statistically signiﬁcant difference in
ocular comfort scores between control and test eyes (mean score
control eye: 5.15±1.57; test eye 5.25±1.33; Z=−0.30;
p=0.76). An improvement in ocular comfort scores over time
was observed over the 2 week treatment period in test eyes
(X2=340.88, p<0.001) but not control eyes (χ2=27.78,
p=0.42), with peak mean ocular comfort score in the test eye
on the morning of Day 14 (8.55±0.89). A statistically signiﬁ-
cant difference in comfort scores between control and test eyes
occurred from the evening on Day 1 (control eye: 5.00±1.45;
test eye: 6.40±1.35; Z=−3.72, p<0.001), and this difference
remained statistically signiﬁcant (p<0.001) for the entire treat-
ment period (ﬁgure 1).
The difference between test and control eyes at baseline was
not statistically signiﬁcant for all measurements (p>0.05;
table 1). After the treatment period, there was a statistically sig-
niﬁcant improvement in all efﬁcacy measurements in test eyes
only (p<0.05), except for meibomian gland expressibility in
control eyes (p<0.05). Visual acuity and corneal topography
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were unaffected (p>0.05), whereas conjunctival hyperaemia and
ocular surface staining decreased in test eyes (table 1).
After 6 months, four patients reported having stopped using
the eyebag, but their ocular comfort was still better than base-
line (6.20±1.03 vs 4.80±1.40, p=0.039). Patients (n=8) who
continued to use the treatment for 1–4 weeks had a greater
ocular comfort beneﬁt (7.79±0.89 vs 5.64±1.33, p<0.001),
but the greatest scores were achieved by those who continued to
use the eyebag 1–8 times a month (7.96±1.46 vs 5.12±1.50,
p<0.001).
One patient reported a transient stinging sensation when the
heated eyebag was placed on the upper eyelid on the ﬁrst four
occasions. No other adverse event was reported by this patient
or the others for the duration of treatment period.
DISCUSSION
The results demonstrate statistically signiﬁcant improvements in
meibomian gland dropout, TMH, osmolarity, conjunctival
hyperaemia and staining in test eyes only (table 1). Given that
measurements were taken on two separate occasions, it was not
possible to determine a natural history of the treatment
approach. It is likely that the frequent and regular heating
melted the abnormal meibum, clearing the obstruction within
the meibomian gland, allowing the meibum to secrete on the
eyelid margin.19 The increased quantity of meibum available
may, therefore, help thicken and restore normal tear ﬁlm lipid
layer function such that evaporation of the underlying aqueous
is prevented, tear ﬁlm stability is improved, tear ﬁlm osmolarity
and ocular surface staining reduced and tear ﬁlm meniscus
height increased.20 This is supported by the signiﬁcant positive
correlation observed between lipid layer thickness and tear ﬁlm
stability.21 Furthermore, meibum quantity or evaporation rates
have previously been shown to positively correlate with tear
ﬁlm stability.22
Indeed, NITBUT (by 1.9±1.3 s) and tear ﬁlm lipid layer
thickness (by 1.1±0.8 grades) demonstrated a statistically
Figure 1 Mean ocular comfort scores
for control eyes and test eyes during
the treatment period (Day 1 to Day
14). Error bars represent 1 SD. The
difference in ocular comfort scores
between control and test eyes was
statistically signiﬁcant (p<0.001) from
the evening of Day 1 onwards.
Table 1 Mean (±1 SD) values for all efficacy and safety parameters for test and control eyes at baseline and follow-up
Baseline Follow-up
Test eye compared
to baseline (p)Control Test Significance Control Test Significance
OSDI 43.0±14.4 43.9±13.4 0.36 39.8±12.7 20.7±8.7 <0.001* <0.001*
Meibomian gland quality 2.40±1.09 2.35±0.99 0.76 2.05±1.23 1.3±0.92 <0.05* <0.001*
Meibomian gland expressibilty 2.00±1.08 2.15±0.89 0.26 1.70±1.03 1.35±0.82 <0.05* <0.001*
Meibomian gland drop-out 2.80±1.24 2.90±1.25 0.41 2.65±1.04 2.05±1.15 <0.05* <0.05*
Osmolarity (mOsm/L) 310.3±10.6 310.9±9.5 0.43 308.9±11.6 305.0±9.1 <0.05* <0.001*
Lipid layer thickness 2.10±0.72 2.05±0.89 0.66 2.2±0.62 3.1±0.91 <0.05* <0.001*
Tear film stability (s) 9.29±3.64 9.48±3.74 0.12 9.32±3.56 11.37±3.45 <0.001* <0.001*
Tear film meniscus height (mm) 0.34±0.06 0.34±0.07 0.69 0.34±0.06 0.36±0.06 <0.001* <0.05*
Visual acuity (LogMAR) −0.04±0.03 −0.04±0.03 0.79 −0.05±0.03 −0.05±0.03 0.42 0.06
Corneal topography (e) 0.37±0.15 0.37±0.16 0.89 0.37±0.15 0.37±0.17 0.91 0.65
Conjunctival hyperaemia vessel coverage 1.86±1.52 1.61±1.19 0.28 1.44±1.06 0.94±0.65 <0.05* <0.05*
Conjunctival hyperaemia coloration 38.81±1.62 38.53±1.66 0.23 38.49±1.42 38.00±1.41 <0.05* <0.05*
Ocular surface staining 3.2±2.06 3.75±1.71 0.07 2.95±1.39 1.85±0.99 <0.05* <0.001*
Asterisks (*) represent statistical significance. Note: conjunctival vessel coverage and colouration an average of superior, inferior, nasal and temporal quadrants as the effect was similar
across ocular surface regions.
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signiﬁcant increase following heat treatment. Although a recent
study investigating the effect of warm moist air goggles in MGD
patients found no statistically signiﬁcant increase in tear ﬁlm sta-
bility 10 min after use,23 Olson et al (2003) found an 80%
increase in lipid layer thickness in MGD-related dry eye patients
after 5 min into treatment with warm moist compress heated to
40°C for 30 min, and 66% increase 5 min after removal.3 Thus,
it may be that improvements in tear ﬁlm stability and lipid layer
thickness in MGD patients can only be achieved where eyelid
warming devices make contact with the eyelids.
Meibomian gland function also improved with the heated
eyebag after the treatment period, where there were statistically
signiﬁcant improvements in meibum quality and expressibility in
test eyes. However, the improvement in meibum quality com-
pared to control eyes was only statistically signiﬁcant between
the lower eyelids. At baseline, meibum quality grade on the
lower eyelid was signiﬁcantly greater than the upper eyelid of
test and control eyes, such that the upper eyelid was considered
normal—thus, improvements in meibum quality may only have
been detected in the lower eyelids owing to the limited reso-
lution of the grading scale. Of interest was the statistically sig-
niﬁcant improvement in expressibility in control eyes
(composite reduction of 0.35±0.81). The non-heated eyebag
may have warmed the eyelids by insulating and preventing heat
loss, which subsequently brought about an improvement in the
abnormal meibum. The frequent application of the eyebag with
the hands may have also massaged the eyelids to help clear the
obstructed glands. Since the heated and non-heated eyebags
were applied at the same time and duration, this massaging
effect may have contributed at least in part to the greater
improvement in expressibility observed in test eyes (composite
reduction of 0.80±0.70). With respect to the semiquantitative
nature of the grading scale, eyelids with 5, 6, or 7 expressible
glands were recorded as ‘grade 1’—thus, the improvements
observed may have been underestimated.
Furthermore, a statistically signiﬁcant improvement in ocular
symptoms was also observed in test eyes only. Surprisingly, the
improvement in ocular comfort scores was observed as early as
the evening of treatment Day 1, suggesting that the eyebag pro-
duces an increase in ocular comfort for at least 12 h following
single use. Although subjects still had raised ocular comfort at
around 6 months after the trial, comfort was maintained best in
those who continued treatment 1–8 times a month. It should be
noted that subjects were not masked and, therefore, some
placebo effect could be possible, although the effect was marked
and occurred in all subjects.
Eyelid warming therapy associated with eyelid massage has
been suggested to induce corneal deformation due to increases
in corneal temperature, and with concurrent massaging, possible
ectasia.24 Only one case of corneal deformation following such
treatment has been reported, but the duration of treatment in
this case was far longer (15 min twice a day for 7 weeks) than
that prescribed herein. Transient visual degradation without
changes in corneal topography has been observed after warm
compresses (45°C) were applied every 2 min for 30 min without
massage,25 but again the duration of treatment and peak tem-
perature was sustained for longer than the present study and the
treatment method is not typically advised to MGD patients.
Therefore, it appears that corneal deformation and/or visual
changes, may only occur following unusually long and intense
treatment application durations and long-term therapy asso-
ciated with eyelid rubbing.
Given there was no reduction in visual acuity and no change
in corneal topography from baseline after the treatment period,
the risk of corneal deformation with the MGDRx EyeBag, as
prescribed, appears to be minimal. Further, there was a statistic-
ally signiﬁcant improvement in ocular surface staining (particu-
larly the cornea) and conjunctival hyperaemia in test eyes. Thus,
when used based upon the treatment regimen prescribed herein,
the MGDRx EyeBag may be considered a safe and effective
eyelid warming device with a low risk of corneal deformation
and visual changes, and results in improved comfort and tear
ﬁlm parameters involved in evaporative dry eye in patients with
MGD.
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